Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses.

Yuko MurashimaShun YamamotoToshiharu HiroseToru KadonoGo IkedaAkihiro OharaMai ItoyamaKazuki YokoyamaYoshitaka HonmaKoshiro IshiyamaJyunya OgumaHiroyuki DaikoKen Kato

Published in: Journal of gastrointestinal cancer (2024)

The efficacy and safety of the two doses of nivolumab monotherapy were comparable in patients with advanced ESCC.

Keyphrases

combination therapy
open label
randomized controlled trial